Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to Sorrell: National Institutes of Health consensus development conference statement: Management.... (0.09 sec) 

National Institutes of Health consensus development conference statement: …


MF Sorrell, EA Belongia, J Costa, IF Gareen, … - Annals of Internal …, 2009 - Am Coll Physicians
National Institutes of Health (NIH) consensus and state-of-the-science statements are prepared
by independent panels of health professionals and public representatives on the basis of 1) the
results of a systematic literature review prepared under contract with the Agency for ...
Cited by 33 - Related articles - All 7 versions

Baseline characteristics and early on-treatment response predict the outcomes of …

- gastrojournal.org
S Zeuzem, E Gane, YF Liaw, SG Lim, A DiBisceglie, M … - Journal of Hepatology, 2009 - Elsevier
Baseline HBV DNA < 9 log 10 copies/mL, or ALT levels 2× above normal were strong pretreatment
predictors for HBeAg-positive, but not for HBeAg-negative patients. However, non-detectable
serum HBV DNA at treatment week 24 (TW24) was the strongest predictor for better ...
Cited by 15 - Related articles - All 21 versions

Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside- …


DJ Tenney, RE Rose, CJ Baldick, KA Pokornowski, … - Hepatology, 2009 - interscience.wiley.com
Patients with chronic hepatitis B virus (HBV) infection who develop antiviral resistance lose benefits
of therapy and may be predisposed to further resistance. Entecavir (ETV) resistance (ETVr) results
from HBV reverse transcriptase substitutions at positions T184, S202, or M250, which ...
Cited by 24 - Related articles - All 2 versions

Treatment of chronic viral hepatitis with nitazoxanide and second generation …


EB Keeffe, JF Rossignol - World Journal of Gastroenterology: …, 2009 - pubmedcentral.nih.gov
Nitazoxanide, the first thiazolide, was originally developed for the treatment of Cryptosporidium
parvum. More recently, antiviral activity of nitazoxanide against hepatitis B virus (HBV) and hepatitis
C virus was recognized in in vitro systems. These basic studies led to phase II clinical ...
Cited by 6 - Related articles - All 8 versions

Entecavir maintains a high genetic barrier to HBV resistance through 6 years in …


DJ Tenney, KA Pokornowski, RE Rose… - J. Hepatol - hivandhepatitis.com
Page 1. Entecavir Maintains a High Genetic Barrier to HBV Resistance Through 6 Years in Naïve
Patients DJ Tenney 1 , KA Pokorowski 1 , RE Rose 1 , CJ Baldick 1 , BJ Eggers 1 , J. Fang 1 ,
MJ Wichroski 1 , U. Diva 1 , D. Xu 1 , RB Wilber 1 , H. Brett-Smith 1 & UH Iloeje 1 ...
Cited by 8 - Related articles - View as HTML

[CITATION] Colchicine versus peg-interferon a 2b long term therapy: results of the 4 year …


NH Afdhal, R Levine, R Brown Jr, B Frielich, M O'Brien, … - J. Hepatol
Cited by 6 - Related articles

[CITATION] Efficacy and safety results of albinterferon α-2b in combination with ribavirin in …


D Nelson, Y Benhamou, WL Chuang… - J. Hepatol
Cited by 7 - Related articles

[CITATION] Efficacy and safety of albinterferon α-2b in combination with ribavirin in treatment- …


S Zeuzem, M Sulkowski, E Lawitz… - J. Hepatol
Cited by 7 - Related articles

[CITATION] First-in-man demonstration of potent antiviral activity with a nucleoside polymerase …


EJ Gane, SK Roberts, C Stedman… - J. Hepatol
Cited by 8 - Related articles

[CITATION] Kinetics of HBsAg decline in HBeAg+ chronic hepatitis B patients with 3 years of …


K Wursthorn, M Jung, M Manns, P Lopez, H … - J. Hepatol
Cited by 9 - Related articles


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google